213 related articles for article (PubMed ID: 32084576)
21. Neuroprotective and Antioxidant Effect of Naringenin-Loaded Nanoparticles for Nose-to-Brain Delivery.
Md S; Alhakamy NA; Aldawsari HM; Asfour HZ
Brain Sci; 2019 Oct; 9(10):. PubMed ID: 31618942
[TBL] [Abstract][Full Text] [Related]
22. A potential tailor-made hyaluronic acid buccal delivery system comprising rotigotine for Parkinson's disease?
Laffleur F; Wagner J; Barthelmes J
Future Med Chem; 2015; 7(10):1225-32. PubMed ID: 26144261
[TBL] [Abstract][Full Text] [Related]
23. Rotigotine transdermal patch for the treatment of Parkinson's Disease.
Perez-Lloret S; Rey MV; Ratti PL; Rascol O
Fundam Clin Pharmacol; 2013 Feb; 27(1):81-95. PubMed ID: 22320451
[TBL] [Abstract][Full Text] [Related]
24. Intranasal Administration of chitosan-Coated Nanostructured Lipid Carriers Loaded with GDNF Improves Behavioral and Histological Recovery in a Partial Lesion Model of Parkinson's Disease.
Gartziandia O; Herrán E; Ruiz-Ortega JA; Miguelez C; Igartua M; Lafuente JV; Pedraz JL; Ugedo L; Hernández RM
J Biomed Nanotechnol; 2016 Dec; 12(12):2220-30. PubMed ID: 29372975
[TBL] [Abstract][Full Text] [Related]
25. Transdermal rotigotine (Neupro) for Parkinson's disease.
Med Lett Drugs Ther; 2007 Aug; 49(1268):69-70. PubMed ID: 17712291
[No Abstract] [Full Text] [Related]
26. Rotigotine: transdermal dopamine agonist treatment of Parkinson's disease and restless legs syndrome.
Splinter MY
Ann Pharmacother; 2007 Feb; 41(2):285-95. PubMed ID: 17213296
[TBL] [Abstract][Full Text] [Related]
27. Outcomes of rotigotine clinical trials: effects on motor and nonmotor symptoms of Parkinson's disease.
Lyons KE; Pahwa R
Neurol Clin; 2013 Aug; 31(3 Suppl):S51-9. PubMed ID: 23931954
[TBL] [Abstract][Full Text] [Related]
28. A novel therapeutic approach to 6-OHDA-induced Parkinson's disease in rats via supplementation of PTD-conjugated tyrosine hydroxylase.
Wu SP; Fu AL; Wang YX; Yu LP; Jia PY; Li Q; Jin GZ; Sun MJ
Biochem Biophys Res Commun; 2006 Jul; 346(1):1-6. PubMed ID: 16762325
[TBL] [Abstract][Full Text] [Related]
29. Rotigotine transdermal patch in the management of Parkinson's disease (PD) and its night-time use for PD-related sleep disorders.
Antonini A; Bernardi L; Calandrella D; Mancini F; Plebani M
Funct Neurol; 2010; 25(1):21-5. PubMed ID: 20626993
[TBL] [Abstract][Full Text] [Related]
30. Quantification and Brain Targeting of Eugenol-Loaded Surface Modified Nanoparticles Through Intranasal Route in the Treatment of Cerebral Ischemia.
Ahmad N; Ahmad R; Alam MA; Ahmad FJ
Drug Res (Stuttg); 2018 Oct; 68(10):584-595. PubMed ID: 29669380
[TBL] [Abstract][Full Text] [Related]
31. Intracarotid Infusion of Mesenchymal Stem Cells in an Animal Model of Parkinson's Disease, Focusing on Cell Distribution and Neuroprotective and Behavioral Effects.
Cerri S; Greco R; Levandis G; Ghezzi C; Mangione AS; Fuzzati-Armentero MT; Bonizzi A; Avanzini MA; Maccario R; Blandini F
Stem Cells Transl Med; 2015 Sep; 4(9):1073-85. PubMed ID: 26198165
[TBL] [Abstract][Full Text] [Related]
32. Rotigotine transdermal system as add-on to oral dopamine agonist in advanced Parkinson's disease: an open-label study.
Kim JM; Chung SJ; Kim JW; Jeon BS; Singh P; Thierfelder S; Ikeda J; Bauer L;
BMC Neurol; 2015 Feb; 15():17. PubMed ID: 25879416
[TBL] [Abstract][Full Text] [Related]
33. Treatment of motor and NMS of Parkinson's disease with the rotigotine transdermal system.
Lyons KE
Neurol Clin; 2013 Aug; 31(3 Suppl):vii-ix. PubMed ID: 23931955
[No Abstract] [Full Text] [Related]
34. Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson disease.
LeWitt PA; Boroojerdi B; MacMahon D; Patton J; Jankovic J
Clin Neuropharmacol; 2007; 30(5):256-65. PubMed ID: 17909303
[TBL] [Abstract][Full Text] [Related]
35. Selegiline Nanoformulation in Attenuation of Oxidative Stress and Upregulation of Dopamine in the Brain for the Treatment of Parkinson's Disease.
Kumar S; Dang S; Nigam K; Ali J; Baboota S
Rejuvenation Res; 2018 Oct; 21(5):464-476. PubMed ID: 29717617
[TBL] [Abstract][Full Text] [Related]
36. Characterization of alginate/chitosan-based nanoparticles and mathematical modeling of their SpBMP-9 release inducing neuronal differentiation of human SH-SY5Y cells.
Lauzon MA; Marcos B; Faucheux N
Carbohydr Polym; 2018 Feb; 181():801-811. PubMed ID: 29254039
[TBL] [Abstract][Full Text] [Related]
37. Transdermal Patch of Rotigotine Attenuates Freezing of Gait in Patients with Parkinson's Disease: An Open-Label Comparative Study of Three Non-Ergot Dopamine Receptor Agonists.
Ikeda K; Hirayama T; Takazawa T; Kawabe K; Iwasaki Y
Intern Med; 2016; 55(19):2765-2769. PubMed ID: 27725534
[TBL] [Abstract][Full Text] [Related]
38. Rotigotine transdermal patch in combination therapy for Parkinson's disease--observations in routine clinical practice.
Ceballos-Baumann A; Häck HJ
Curr Med Res Opin; 2011 Oct; 27(10):1899-905. PubMed ID: 21867400
[TBL] [Abstract][Full Text] [Related]
39. Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting.
Fazil M; Md S; Haque S; Kumar M; Baboota S; Sahni JK; Ali J
Eur J Pharm Sci; 2012 Aug; 47(1):6-15. PubMed ID: 22561106
[TBL] [Abstract][Full Text] [Related]
40. Transdermal iontophoresis of rotigotine across human stratum corneum in vitro: influence of pH and NaCl concentration.
Nugroho AK; Li GL; Danhof M; Bouwstra JA
Pharm Res; 2004 May; 21(5):844-50. PubMed ID: 15180344
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
